June 2011 BERTA, a research Project of Aromics on anticancer compounds, has been approved by the EurotransBIO Initiative


The project called BERberine new derivatives as anti Tumour Agents for cancer therapy (BERTA) is a European collaborative project under the Era-NET EurotransBIO coordinated by the Italian company Naxospharma, and with AROMICS (Spain) and the Fondazione IRCCS Istituto Nazionale Tumori (Italy) as partners.


BERTA is a 850,000€ three-year project starting next September 2011 which aims at the Preclinical characterization and early development of berberine derivatives as anticancer New Chemical Entities for the treatment of malignant mesotheliomas.

The project is among the 15 approved proposals out of 42 that were submitted to the 6th ETB Call on February 1st, 2011.


AROMICS will contribute to the project with its wide expertise in pre-clinical research applying a wide range of functional genomics and proteomics technologies to study the in-vitro efficacy, mechanism of action and preliminary ADME profile of the novel berberine derivative compounds.


EurotransBIO coordinates different EU Member States national/regional public funding programmes aiming at fostering economic and academic biotech players in sharing risks, costs and skills in order to develop new products and technologies that could reach the market in the short/medium term.

ACC1Ó, the Catalan Innovation Agency, is the public body supporting the participation of Catalan entities in the ETB initiative.